Results presented at the American Diabetes Association’s 79th Scientific Sessions have shown that Invokana (canagliflozin) significantly reduces the risk of major cardiovascular (CV) events and kidney failure in patients with type II diabetes mellitus and chronic kidney disease (CKD), with and without known CV disease.

A sub-group analysis found that the Janssen drug, distributed in the UK by Napp Pharmaceuticals, provided consistent CV and renal protection across both subgroups when compared to the overall study population. It reduced the risk of the composite of CV death, heart attack and stroke by 32% in the primary prevention group and 15% in the secondary prevention group, as well as end stage kidney disease by 31% and 33% in the primary and secondary prevention groups, respectively.

The CREDENCE study is the first dedicated renal outcome trial evaluating renal and cardiovascular outcomes in people with type II diabetes mellitus and kidney disease with a sodium glucose co-transporter 2 (SGLT2) inhibitor.

“Cardiovascular disease and kidney disease are two serious complications of type II diabetes that may shorten life expectancy by several years,” explained Professor of kidney medicine, David Wheeler.

He continued, “This latest analysis of the CREDENCE study demonstrates that for patients with type II diabetes and chronic kidney disease, canagliflozin reduced the risk of a cardiovascular event, whether or not patients had already experienced one. Thus, early treatment may help to prevent clinical manifestations of cardiovascular disease - an important message for healthcare professionals managing these patients.”

There are more than three million people with CKD requiring renal replacement therapy globally, and this number is likely to increase to more than five million by 2030. People affected by CKD have a reduced life expectancy and lower quality of life, as well as a substantially increased risk of cardiovascular disease and other adverse health outcomes.